Transcript Microbiology

RAPP-ID
Development of RApid Point-of-Care
test Platforms for Infectious Diseases
Herman Goossens, MD, PhD
University of Antwerp, Belgium
Academic Coordinator
Jorge Villacian, MD
Johnson & Johnson, Belgium
Project Coordinator
Why do we need better Rapid Point-of-Care
Tests?
• There has been under-investment in rapid diagnostics for
improving the quality of care for patients with suspected
infections:
– Diagnostics influence 60-70% of health care decision making but
account for less than 5% of hospital costs (Lewin report 2006)
• POCTs improve antibiotic targeting to only those who will
benefit, thus reducing overuse:
– The commonest reason for prescribing antibiotics in the community is
acute cough, and these prescriptions virtually never benefit patients
(Butler et al, BMJ 2009)
RAPP-ID
Why do we need better Rapid Point-of-Care
Tests?
• POCTs enhance surveillance of pathogens and infectious
diseases:
– e.g. H1N1 flu pandemic
• POCTs support rapid initiation and cessation of treatment:
– Sepsis is associated with 7% increased mortality for every hour delay in
the administration of appropriate antibiotics (Kumar el al, CCM 2006).
• POCTs decrease the size and cost of antibacterial clinical trials:
– We URGENTLY need new antibiotics (ECDC/EMA report 2009)
RAPP-ID
Why did Industry and Academia Fail?
Can you imagine the
challenges of shrinking a
huge laboratory filled with
people and equipment
onto a single chip the size
of a matchbox?
Neither industry,
nor academia
can do this on
their own!
Ziober et al. Head Neck 2008
RAPP-ID
Overall Objective
RAPP-ID will develop a Point-of-Care Test
(POCT) for rapid (hospital <2h, primary care
<30min) detection of bacteria, mycobacteria,
fungi, as well as viruses and host
biomarkers by combining novel specific
probes, novel methods of sample preparation,
and demonstrated ultra-high sensitive
detection methods. The platforms will also
determine resistance to antimicrobial drugs
RAPP-ID
RAPP-ID Meets Clearly Defined Clinician Needs
• Sepsis
• Lower Respiratory Tract Infections (LRTI)
– Community-Acquired Pneumonia (CAP)
– Ventilator-Associated Pneumonia (VAP)
• Tuberculosis (TB)
RAPP-ID
RAPP-ID Project Phases
RAPP-ID
Consortium Synergies
• Academic partners:
–
–
–
–
Expertise in European Projects
Innovative technologies
Clinical expertise
Samples/Laboratory capabilities
• SME:
– Innovative technologies
– Flexible attitude
• EFPIA
–
–
–
–
Industry perspective
Expertise in clinical development
Regulatory and communication expertise
Samples/Laboratory capabilities
RAPP-ID
Why Should RAPP-ID Succeed?
• IMI is a unique instrument of joint academia-industry initiatives,
and this is the ONLY way to successfully develop POCT for
Infectious Diseases
• RAPP-ID partners have built up experience in other EU funded
projects (GRACE, InTopSens, TheraEDGE, ...)
• RAPP-ID provides a unique combination of a whole range of
novel assays and technologies
• POCT development will not only be “pathogen or
technologically driven’ but also designed to meet clearly defined
clinical needs with optimal integration and implementation into
diagnostic/clinical algorithms and healthcare programs
RAPP-ID
Visit Our Website: www.rapp-id.eu
RAPP-ID